EUROTOX 2026 | Booth: 53
September 13-16, 2026 | Vienna, Austria
LifeNet Health LifeSciences is proud to attend EUROTOX 2026 in Vienna, Austria, where we’ll showcase human-relevant solutions designed to support toxicology, safety assessment, and translational research. Visit Booth #53 to explore our portfolio of primary human cells, in vitro assay services, prospective human biospecimens, and advanced in vitro models, including our integrated multi-organ microphysiological system (MPS). Our scientific team will also present two poster presentations, highlighting new research in a scalable 3D primary human thyroid microtissue model for the identification of thyroid-disrupting chemicals and a study on the integration of in vitro permeation testing with in silico modeling to predict dermal absorption.
Join us at our scientific presentations:
Poster presentation: “A Scalable Primary Human 3D Thyroid Microtissue NAM for Identification of Thyroid Disrupting Chemicals”
Key Highlights • Human-relevant 3D thyroid model Primary human thyrocytes form functional 3D microtissues that enable mechanistic assessment of thyroid hormone disruption across multiple molecular initiating events. • Robust, reproducible assay performance The 96-well assay demonstrated strong screening characteristics, including Z′-factors >0.6, CVs <30%, and >2.5-fold signal-to-background, with concentration-dependent inhibition of T4 synthesis by established thyroid-disrupting chemicals. • Scalable for high-throughput screening Successful adaptation to a 384-well format demonstrated biological responsiveness and supports efficient chemical prioritization and weight-of-evidence assessments aligned with European endocrine disruptor identification frameworks.
.png&w=3840&q=100)
Presenter: Eda Rogers, PhD
- Date / time:
- Monday, 14 September 2026 at 9:30 am
- Session:
- P18 – In silico and in vitro methods
- Location:
- Room 0.11-0.12 (11-12)
- Poster:
- P18-50
.png&w=3840&q=100)
Poster presentation: “Predicting Dermal Absorption Through Integrated In Silico Modeling and In Vitro Permeation Testing (IVPT)”
Key Highlights • Integrating IVPT with in silico modeling Combining excised human skin IVPT with mechanistic skin permeation modeling provides complementary data to support predictions of dermal absorption and systemic exposure. • Human skin testing captured compound-specific absorption IVPT demonstrated clear differences in dermal disposition across four compounds, from no detectable absorption for mannitol to 14.84 µg/cm² for caffeine after 24 hours, highlighting the influence of physicochemical properties on skin permeation. • Supporting a weight-of-evidence NAM strategy In silico simulations captured key qualitative patterns observed experimentally—including minimal mannitol permeation and strong testosterone surface retention—demonstrating the potential to combine NAMs for more robust, human-relevant dermal risk assessment.
.png&w=3840&q=100)
Presenter: Jamin Willoughby Sr., PhD
- Date / time:
- Tuesday, 15 September 2026 at 12:15 pm
- Session:
- P:30 – Risk Prediction and Assessment/Risk assessment using New Approach Methodologies
- Location:
- Room 0.11 – 0.12 (11-12)
- Poster:
- P30-99
.png&w=3840&q=100)